We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NVS Inks a Licensing Deal With Arrowhead for siRNA Therapy
Read MoreHide Full Article
Key Takeaways
Novartis licensed Arrowhead's preclinical ARO-SNCA therapy for Parkinsons and related disorders.
ARWR will handle preclinical work, then NVS takes over development, manufacturing, and sales.
Arrowhead gains $200 million upfront plus up to $2 billion in milestones and royalties on future sales.
Novartis ((NVS - Free Report) ) has entered into a licensing and collaboration agreement with Arrowhead Pharmaceuticals, Inc. () for the latter’s ARO-SNCA.
ARO-SNCA is Arrowhead’s preclinical stage siRNA therapy against alpha-synuclein for the treatment of synucleinopathies, such as Parkinson’s Disease, and other additional collaboration targets.
With this licensing deal, bigwig Novartis aims to develop a treatment for the complex Parkinson’s Disease, which affects millions of patients worldwide.
Shares of Novartis have gained 33.2% year to date compared with the industry’s gain of 1.8%.
Image Source: Zacks Investment Research
More on NVS’ Deal With ARWR
Novartis will receive an exclusive worldwide license to research, develop, manufacture, and commercialize ARO-SNCA, which utilizes Arrowhead’s Targeted RNAi Molecule (TRiM) platform. Novartis also has the option to select additional collaboration targets outside Arrowhead’s current pipeline for development using the TRiM platform.
Arrowhead is responsible for conducting and completing preclinical research activities necessary to enable a clinical trial application filing for all licensed programs under the agreement. Thereafter, Novartis will assume sole control over development, manufacturing, medical affairs, and commercialization activities.
Per the terms of the deal, Novartis will make an upfront payment of $200 million to Arrowhead and the latter is also eligible to receive is eligible to receive up to $2 billion in potential milestone payments plus royalties on commercial sales.
The transaction is expected to be closed in the second half of 2025.
Shares of ARWR gained 16.57% on Sept. 2 as investors are upbeat about the cash influx.
NVS Looks to Broaden Portfolio
Novartis’ performance has been strong in the past few quarters, driven by the solid performance of its key brands.
Approval of new drugs and label expansion of existing drugs should enable the company to offset the adverse impacts of generic competition for Tasigna and Promacta.
While organic growth continues to drive business, NVS is focused on strategic acquisitions and deals to strengthen its pipeline.
Developing a treatment for neurodegenerative diseases like Parkinson’s Disease is a challenging affair, and many pharma giants are trying their hands at it.
NVS had earlier faced a setback in this space. We remind investors that Novartis was developing minzasolmin (oral small molecule, alpha-synuclein misfolding inhibitor) with Belgium-based UCB for Parkinson’s Disease. However, the candidate did not meet its primary and secondary clinical endpoints in the ORCHESTRA proof-of-concept study, and the program was terminated.
In June 2025, another Swiss pharma giant, Roche ((RHHBY - Free Report) ), announced its decision to proceed with phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson’s disease.
The decision was based on data from the phase IIb PADOVA study and ongoing open-label extensions (OLEs) of PADOVA and phase II PASADENA studies.
Data from the PADOVA and OLE studies suggest a potential clinical benefit of prasinezumab when added to effective symptomatic treatment in early-stage Parkinson’s disease. While prasinezumab showed potential clinical efficacy in the primary endpoint of time to confirmed motor progression, it did not reach statistical significance.
In December 2013, Roche entered into a licensing agreement with Prothena to develop and commercialize monoclonal antibodies targeting aggregated alpha-synuclein, such as prasinezumab, for the treatment of Parkinson’s Disease.
Image: Bigstock
NVS Inks a Licensing Deal With Arrowhead for siRNA Therapy
Key Takeaways
Novartis ((NVS - Free Report) ) has entered into a licensing and collaboration agreement with Arrowhead Pharmaceuticals, Inc. () for the latter’s ARO-SNCA.
ARO-SNCA is Arrowhead’s preclinical stage siRNA therapy against alpha-synuclein for the treatment of synucleinopathies, such as Parkinson’s Disease, and other additional collaboration targets.
With this licensing deal, bigwig Novartis aims to develop a treatment for the complex Parkinson’s Disease, which affects millions of patients worldwide.
Shares of Novartis have gained 33.2% year to date compared with the industry’s gain of 1.8%.
Image Source: Zacks Investment Research
More on NVS’ Deal With ARWR
Novartis will receive an exclusive worldwide license to research, develop, manufacture, and commercialize ARO-SNCA, which utilizes Arrowhead’s Targeted RNAi Molecule (TRiM) platform. Novartis also has the option to select additional collaboration targets outside Arrowhead’s current pipeline for development using the TRiM platform.
Arrowhead is responsible for conducting and completing preclinical research activities necessary to enable a clinical trial application filing for all licensed programs under the agreement. Thereafter, Novartis will assume sole control over development, manufacturing, medical affairs, and commercialization activities.
Per the terms of the deal, Novartis will make an upfront payment of $200 million to Arrowhead and the latter is also eligible to receive is eligible to receive up to $2 billion in potential milestone payments plus royalties on commercial sales.
The transaction is expected to be closed in the second half of 2025.
Shares of ARWR gained 16.57% on Sept. 2 as investors are upbeat about the cash influx.
NVS Looks to Broaden Portfolio
Novartis’ performance has been strong in the past few quarters, driven by the solid performance of its key brands.
Approval of new drugs and label expansion of existing drugs should enable the company to offset the adverse impacts of generic competition for Tasigna and Promacta.
While organic growth continues to drive business, NVS is focused on strategic acquisitions and deals to strengthen its pipeline.
Developing a treatment for neurodegenerative diseases like Parkinson’s Disease is a challenging affair, and many pharma giants are trying their hands at it.
NVS had earlier faced a setback in this space. We remind investors that Novartis was developing minzasolmin (oral small molecule, alpha-synuclein misfolding inhibitor) with Belgium-based UCB for Parkinson’s Disease. However, the candidate did not meet its primary and secondary clinical endpoints in the ORCHESTRA proof-of-concept study, and the program was terminated.
In June 2025, another Swiss pharma giant, Roche ((RHHBY - Free Report) ), announced its decision to proceed with phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson’s disease.
The decision was based on data from the phase IIb PADOVA study and ongoing open-label extensions (OLEs) of PADOVA and phase II PASADENA studies.
Data from the PADOVA and OLE studies suggest a potential clinical benefit of prasinezumab when added to effective symptomatic treatment in early-stage Parkinson’s disease. While prasinezumab showed potential clinical efficacy in the primary endpoint of time to confirmed motor progression, it did not reach statistical significance.
In December 2013, Roche entered into a licensing agreement with Prothena to develop and commercialize monoclonal antibodies targeting aggregated alpha-synuclein, such as prasinezumab, for the treatment of Parkinson’s Disease.
NVS’ Zacks Rank
Novartis currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.